CVS Health Corporation
Get $10 bonus on your first $100 deposit for CVS
Get $10 bonus on your first $100 deposit for CVS
CVS Health Corporation (CVS) Stock Competitors & Peer Comparison
See (CVS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CVS | $72.84 | +0.48% | 93.5B | 52.87 | $1.39 | +3.62% |
| UNH | $281.94 | +2.91% | 251.7B | 20.96 | $13.23 | +3.19% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.00% |
| CI | $272.49 | +1.93% | 72.1B | 12.17 | $22.19 | +2.26% |
| ELV | $302.44 | +1.32% | 66.4B | 11.93 | $25.20 | +2.28% |
| HUM | $181.76 | +2.72% | 21.4B | 18.07 | $9.84 | +1.99% |
| CNC | $35.38 | +4.20% | 17.3B | -2.59 | -$13.53 | N/A |
| MOH | $143.56 | +5.70% | 7.2B | 15.63 | $8.92 | N/A |
| ALHC | $18.82 | +5.43% | 3.8B | -170.55 | -$0.11 | N/A |
| OSCR | $12.28 | +4.69% | 3.1B | -7.05 | -$1.69 | N/A |
Stock Comparison
CVS vs UNH Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, UNH has a market cap of 251.7B. Regarding current trading prices, CVS is priced at $72.84, while UNH trades at $281.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas UNH's P/E ratio is 20.96. In terms of profitability, CVS's ROE is +0.02%, compared to UNH's ROE of +0.13%. Regarding short-term risk, CVS is more volatile compared to UNH. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check UNH's competition here
CVS vs ANTM Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, CVS is priced at $72.84, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas ANTM's P/E ratio is 18.99. In terms of profitability, CVS's ROE is +0.02%, compared to ANTM's ROE of +0.13%. Regarding short-term risk, CVS is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check ANTM's competition here
CVS vs CI Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, CI has a market cap of 72.1B. Regarding current trading prices, CVS is priced at $72.84, while CI trades at $272.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas CI's P/E ratio is 12.17. In terms of profitability, CVS's ROE is +0.02%, compared to CI's ROE of +0.15%. Regarding short-term risk, CVS is more volatile compared to CI. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check CI's competition here
CVS vs ELV Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, ELV has a market cap of 66.4B. Regarding current trading prices, CVS is priced at $72.84, while ELV trades at $302.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas ELV's P/E ratio is 11.93. In terms of profitability, CVS's ROE is +0.02%, compared to ELV's ROE of +0.13%. Regarding short-term risk, CVS is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check ELV's competition here
CVS vs HUM Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, HUM has a market cap of 21.4B. Regarding current trading prices, CVS is priced at $72.84, while HUM trades at $181.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas HUM's P/E ratio is 18.07. In terms of profitability, CVS's ROE is +0.02%, compared to HUM's ROE of +0.07%. Regarding short-term risk, CVS is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check HUM's competition here
CVS vs CNC Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, CNC has a market cap of 17.3B. Regarding current trading prices, CVS is priced at $72.84, while CNC trades at $35.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas CNC's P/E ratio is -2.59. In terms of profitability, CVS's ROE is +0.02%, compared to CNC's ROE of -0.28%. Regarding short-term risk, CVS is more volatile compared to CNC. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check CNC's competition here
CVS vs MOH Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, MOH has a market cap of 7.2B. Regarding current trading prices, CVS is priced at $72.84, while MOH trades at $143.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas MOH's P/E ratio is 15.63. In terms of profitability, CVS's ROE is +0.02%, compared to MOH's ROE of +0.11%. Regarding short-term risk, CVS is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check MOH's competition here
CVS vs ALHC Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, ALHC has a market cap of 3.8B. Regarding current trading prices, CVS is priced at $72.84, while ALHC trades at $18.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas ALHC's P/E ratio is -170.55. In terms of profitability, CVS's ROE is +0.02%, compared to ALHC's ROE of -0.00%. Regarding short-term risk, CVS is more volatile compared to ALHC. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check ALHC's competition here
CVS vs OSCR Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, OSCR has a market cap of 3.1B. Regarding current trading prices, CVS is priced at $72.84, while OSCR trades at $12.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas OSCR's P/E ratio is -7.05. In terms of profitability, CVS's ROE is +0.02%, compared to OSCR's ROE of -0.39%. Regarding short-term risk, CVS is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check OSCR's competition here
CVS vs CLOV Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, CLOV has a market cap of 880.6M. Regarding current trading prices, CVS is priced at $72.84, while CLOV trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas CLOV's P/E ratio is -10.12. In terms of profitability, CVS's ROE is +0.02%, compared to CLOV's ROE of -0.26%. Regarding short-term risk, CVS is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check CLOV's competition here
CVS vs BHG Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, CVS is priced at $72.84, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas BHG's P/E ratio is -0.12. In terms of profitability, CVS's ROE is +0.02%, compared to BHG's ROE of -0.70%. Regarding short-term risk, CVS is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check BHG's competition here
CVS vs CABR Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, CABR has a market cap of 16.4M. Regarding current trading prices, CVS is priced at $72.84, while CABR trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas CABR's P/E ratio is -2.41. In terms of profitability, CVS's ROE is +0.02%, compared to CABR's ROE of N/A. Regarding short-term risk, CVS is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check CABR's competition here
CVS vs BMGL Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, BMGL has a market cap of 11.2M. Regarding current trading prices, CVS is priced at $72.84, while BMGL trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas BMGL's P/E ratio is -1.35. In terms of profitability, CVS's ROE is +0.02%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, CVS is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check BMGL's competition here
CVS vs MRAI Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, MRAI has a market cap of 5.7M. Regarding current trading prices, CVS is priced at $72.84, while MRAI trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas MRAI's P/E ratio is -0.11. In terms of profitability, CVS's ROE is +0.02%, compared to MRAI's ROE of +0.52%. Regarding short-term risk, CVS is more volatile compared to MRAI. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check MRAI's competition here
CVS vs NIVF Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, NIVF has a market cap of 1.2M. Regarding current trading prices, CVS is priced at $72.84, while NIVF trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas NIVF's P/E ratio is 0.06. In terms of profitability, CVS's ROE is +0.02%, compared to NIVF's ROE of +1.17%. Regarding short-term risk, CVS is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check NIVF's competition here
CVS vs GTS Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, GTS has a market cap of 0. Regarding current trading prices, CVS is priced at $72.84, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas GTS's P/E ratio is 10.41. In terms of profitability, CVS's ROE is +0.02%, compared to GTS's ROE of +0.07%. Regarding short-term risk, CVS is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check GTS's competition here
CVS vs AET Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, AET has a market cap of 0. Regarding current trading prices, CVS is priced at $72.84, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas AET's P/E ratio is N/A. In terms of profitability, CVS's ROE is +0.02%, compared to AET's ROE of +0.11%. Regarding short-term risk, CVS is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check AET's competition here
CVS vs MGLN Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, CVS is priced at $72.84, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas MGLN's P/E ratio is 8.49. In terms of profitability, CVS's ROE is +0.02%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, CVS is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check MGLN's competition here
CVS vs UAM Comparison April 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 93.5B. In comparison, UAM has a market cap of 0. Regarding current trading prices, CVS is priced at $72.84, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 52.87, whereas UAM's P/E ratio is N/A. In terms of profitability, CVS's ROE is +0.02%, compared to UAM's ROE of +0.17%. Regarding short-term risk, CVS is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check UAM's competition here